Filter

Refine by date

—

Refine by collections

  • Print
  • Save

Search Results

You are looking at 1 - 10 of 20 items for :

Clear All
Lars Bastholt Department of Oncology R, Odense University Hospital, Odense, Denmark

Search for other papers by Lars Bastholt in
Google Scholar
PubMed Close
,
Michael C. Kreissl Department of Nuclear Medicine, Augsburg Hospital, Augsburg
Department of Nuclear Medicine, University Hospital Würzburg, Würzburg

Search for other papers by Michael C. Kreissl in
Google Scholar
PubMed Close
,
Dagmar Führer Department of Endocrinology and Metabolism, University Hospital Essen, Essen, Germany

Search for other papers by Dagmar Führer in
Google Scholar
PubMed Close
,
Ana L. Maia Serviço de Endocrinologia, Hospital de Clínicas de Porto Alegre, Porto Alegre

Search for other papers by Ana L. Maia in
Google Scholar
PubMed Close
,
Laura D. Locati Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan

Search for other papers by Laura D. Locati in
Google Scholar
PubMed Close
,
Léa Maciel Hospital das Clínicas de Ribeirăo Preto, Ribeirăo Preto, Brazil

Search for other papers by Léa Maciel in
Google Scholar
PubMed Close
,
Yi Wu Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, China

Search for other papers by Yi Wu in
Google Scholar
PubMed Close
,
Kevin N. Heller AstraZeneca, Gaithersburg, Md., USA

Search for other papers by Kevin N. Heller in
Google Scholar
PubMed Close
,
Alan Webster AstraZeneca, Macclesfield, UK

Search for other papers by Alan Webster in
Google Scholar
PubMed Close
, and
Rossella Elisei Endocrinology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy

Search for other papers by Rossella Elisei in
Google Scholar
PubMed Close

contribute to the growth and invasiveness of MTC [ 11 , 12 ]. Vandetanib is a once-daily oral multikinase inhibitor directed against VEGFR2, RET and EGFR [ 9 , 13 ]. In the EU, vandetanib is indicated for the treatment of aggressive and symptomatic MTC in

Article Type:
Research Article
DOI:
https://doi.org/10.1159/000448919
Volume/Issue:
Volume 5: Issue 3
Free access
Camille Buffet Department of Thyroid Pathologies and Endocrine Tumors, AP-HP, Pitié-Salpêtrière Hospital, Groupe de Recherche Clinique n°16 Tumeurs Thyroïdiennes, Sorbonne Université, Paris, France
UMR9019, Genome Integrity and Cancers, CNRS, Villejuif, France

Search for other papers by Camille Buffet in
Google Scholar
PubMed Close
,
Sophie Leboulleux Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy Institut, Villejuif, France

Search for other papers by Sophie Leboulleux in
Google Scholar
PubMed Close
,
Françoise Kraeber-Bodéré Nuclear Medicine Department, Université de Nantes, CHU de Nantes, CNRS, Inserm, CRCINA, Nantes, France
CHU Nantes/ICO, Saint-Herblain, France

Search for other papers by Françoise Kraeber-Bodéré in
Google Scholar
PubMed Close
,
Caroline Bodet-Milin Nuclear Medicine Department, Université de Nantes, CHU de Nantes, CNRS, Inserm, CRCINA, Nantes, France
CHU Nantes/ICO, Saint-Herblain, France

Search for other papers by Caroline Bodet-Milin in
Google Scholar
PubMed Close
,
Laure Cabanes Department of Cardiology, APHP, Cochin Hospital, Paris, France
Université de Paris, Paris, France

Search for other papers by Laure Cabanes in
Google Scholar
PubMed Close
,
Anthony Dohan Radiology Department, Université de Paris, Paris, France
Department of Radiology, AP-HP, Hôpital Cochin, Paris, France

Search for other papers by Anthony Dohan in
Google Scholar
PubMed Close
,
Pascal Leprince Department of Thoracic and Cardiovascular Surgery, Sorbonne Université, AP-HP, Pitié-Salpêtrière Hospital, Paris, France

Search for other papers by Pascal Leprince in
Google Scholar
PubMed Close
,
Martin Schlumberger UMR9019, Genome Integrity and Cancers, CNRS, Villejuif, France
Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy Institute, Villejuif, France

Search for other papers by Martin Schlumberger in
Google Scholar
PubMed Close
,
Olivier Huillard Université de Paris, Sorbonne Paris Cité, Paris, France
Department of Medical Oncology, AP-HP, Hôpital Cochin, Paris, France

Search for other papers by Olivier Huillard in
Google Scholar
PubMed Close
, and
Lionel Groussin INSERM Unité 1016, CNRS UMR 8104, Institut Cochin, Paris, France
Université de Paris, Paris, France
Department of Endocrinology, AP-HP, Hôpital Cochin, Paris, France

Search for other papers by Lionel Groussin in
Google Scholar
PubMed Close

with long-term outcome under the tyrosine kinase inhibitor vandetanib. Patient 1 A 45-year-old woman was diagnosed with MTC after total thyroidectomy and neck dissection (Fig.  1 a). Histology revealed an 11-mm thyroid tumor with minimal extra

Article Type:
Case Report
DOI:
https://doi.org/10.1159/000517716
Volume/Issue:
Volume 10: Issue 6
Open access
Zoe A. Efstathiadou Department of Endocrinology, “Hippokration” General Hospital of Thessaloniki, Thessaloniki, Greece

Search for other papers by Zoe A. Efstathiadou in
Google Scholar
PubMed Close
,
Charalambos Tsentidis Department of Endocrinology, General Hospital of Nikaia “Agios Panteleimon”, Piraeus, Greece

Search for other papers by Charalambos Tsentidis in
Google Scholar
PubMed Close
,
Alexandra Bargiota Department of Endocrinology, University of Thessaly, Larisa, Greece

Search for other papers by Alexandra Bargiota in
Google Scholar
PubMed Close
,
Vasiliki Daraki Department of Endocrinology, University Hospital of Crete, Heraklion, Greece

Search for other papers by Vasiliki Daraki in
Google Scholar
PubMed Close
,
Kalliopi Kotsa Department of Endocrinology, “Ahepa” Hospital, Aristotle University, Thessaloniki, Greece

Search for other papers by Kalliopi Kotsa in
Google Scholar
PubMed Close
,
Georgia Ntali Department of Endocrinology, Diabetes and Metabolism, “Evangelismos” Hospital Athens, Athens, Greece

Search for other papers by Georgia Ntali in
Google Scholar
PubMed Close
,
Labrini Papanastasiou Department of Endocrinology and Diabetes Center, Athens General Hospital “G. Gennimatas”, Athens, Greece

Search for other papers by Labrini Papanastasiou in
Google Scholar
PubMed Close
,
Stelios Tigas Department of Endocrinology, University of Ioannina, Ioannina, Greece

Search for other papers by Stelios Tigas in
Google Scholar
PubMed Close
,
Konstantinos Toulis Department of Endocrinology, 424 Military Hospital, Thessaloniki, Greece

Search for other papers by Konstantinos Toulis in
Google Scholar
PubMed Close
,
Kalliopi Pazaitou-Panayiotou Division of Endocrinology, Endocrine Oncology, Interbalkan Medical Center, Thessaloniki, Greece

Search for other papers by Kalliopi Pazaitou-Panayiotou in
Google Scholar
PubMed Close
, and
Maria Alevizaki Endocrine Unit, Department of Medical Therapeutics, School of Medicine, Kapodistrian University of Athens, Athens, Greece

Search for other papers by Maria Alevizaki in
Google Scholar
PubMed Close

vandetanib inhibit multiple kinases including RET and VEGFR. Among others, signaling pathways initiated by both RET and VEGFR are important for MTC development and progression [ 3 , 7 ]. Although promising, these drugs show only a modest effect on advanced

Article Type:
Meta Analysis
DOI:
https://doi.org/10.1159/000509457
Volume/Issue:
Volume 10: Issue 2
Free access
Carla Colombo Endocrine Oncology Unit, Department of Endocrine and Metabolic Diseases, Istituto Auxologico Italiano IRCCS, Milan, Italy
Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy

Search for other papers by Carla Colombo in
Google Scholar
PubMed Close
,
Daniele Ceruti Department of Biotechnology and Translational Medicine, University of Milan, Milan, Italy

Search for other papers by Daniele Ceruti in
Google Scholar
PubMed Close
,
Massimiliano Succi Department of Biotechnology and Translational Medicine, University of Milan, Milan, Italy

Search for other papers by Massimiliano Succi in
Google Scholar
PubMed Close
,
Simone De Leo Endocrine Oncology Unit, Department of Endocrine and Metabolic Diseases, Istituto Auxologico Italiano IRCCS, Milan, Italy

Search for other papers by Simone De Leo in
Google Scholar
PubMed Close
,
Matteo Trevisan Endocrine Oncology Unit, Department of Endocrine and Metabolic Diseases, Istituto Auxologico Italiano IRCCS, Milan, Italy
Department of Biotechnology and Translational Medicine, University of Milan, Milan, Italy

Search for other papers by Matteo Trevisan in
Google Scholar
PubMed Close
,
Claudia Moneta Department of Biotechnology and Translational Medicine, University of Milan, Milan, Italy

Search for other papers by Claudia Moneta in
Google Scholar
PubMed Close
, and
Laura Fugazzola Endocrine Oncology Unit, Department of Endocrine and Metabolic Diseases, Istituto Auxologico Italiano IRCCS, Milan, Italy
Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy

Search for other papers by Laura Fugazzola in
Google Scholar
PubMed Close

Europe, the multikinase inhibitors sorafenib, lenvatinib (LEN) and cabozantinib have been approved for RAI-R DTC, vandetanib (VAN) and cabozantinib for MTC, and the gene-targeted selpercatinib (SELP) and larotrectinib for cancers harbouring rearranged

Article Type:
Research Article
Collections:
Thyroid cancer - basic and translational
DOI:
https://doi.org/10.1530/ETJ-23-0246
Volume/Issue:
Volume 13: Issue 3
Open access
Grace Segall Eli Lilly and Company, Indianapolis, IN, USA

Search for other papers by Grace Segall in
Google Scholar
PubMed Close
,
Ravinder Singh Eli Lilly and Company, Indianapolis, IN, USA

Search for other papers by Ravinder Singh in
Google Scholar
PubMed Close
,
Min-Hua Jen Eli Lilly and Company, Indianapolis, IN, USA

Search for other papers by Min-Hua Jen in
Google Scholar
PubMed Close
,
Isaac Sanderson Adelphi Real World, Bollington, UK

Search for other papers by Isaac Sanderson in
Google Scholar
PubMed Close
,
Alex Rider Adelphi Real World, Bollington, UK

Search for other papers by Alex Rider in
Google Scholar
PubMed Close
,
Katie Lewis Adelphi Real World, Bollington, UK

Search for other papers by Katie Lewis in
Google Scholar
PubMed Close
, and
Urpo Kiiskinen Eli Lilly and Company, Indianapolis, IN, USA

Search for other papers by Urpo Kiiskinen in
Google Scholar
PubMed Close

recommend the MKIs cabozantinib and vandetanib as first-line systemic therapy, and the selective RET inhibitor selpercatinib for patients with RET mutation-positive MTC who require systemic therapy following prior treatment with cabozantinib and

Article Type:
Research Article
Collections:
Thyroid cancer - clinical
DOI:
https://doi.org/10.1530/ETJ-23-0172
Volume/Issue:
Volume 13: Issue 1
Open access
Marine Sitbon Pharmacy Department, Hospital Saint-Louis APHP, Paris, France

Search for other papers by Marine Sitbon in
Google Scholar
PubMed Close
,
Porhuoy Chou Endocrine Oncology Department, Saint-Louis Hospital (AP-HP), Université Paris Cité, Paris, France

Search for other papers by Porhuoy Chou in
Google Scholar
PubMed Close
,
Seydou Bengaly Endocrine Oncology Department, Saint-Louis Hospital (AP-HP), Université Paris Cité, Paris, France

Search for other papers by Seydou Bengaly in
Google Scholar
PubMed Close
,
Brigitte Poirot Department of Molecular Oncology, Saint-Louis Hospital (AP-HP), Université Paris Cité INSERM U 944, CNRS UMR 7212, Paris, France

Search for other papers by Brigitte Poirot in
Google Scholar
PubMed Close
,
Marie Laloi-Michelin Department of Internal Medicine, Hospital Lariboisière APHP, Paris, France

Search for other papers by Marie Laloi-Michelin in
Google Scholar
PubMed Close
,
Laure Deville Pharmacy Department, Hospital Saint-Louis APHP, Paris, France

Search for other papers by Laure Deville in
Google Scholar
PubMed Close
,
Atanas Pachev Radiology Department, Saint-Louis Hospital (AP-HP), Université Paris Cité, Paris, France

Search for other papers by Atanas Pachev in
Google Scholar
PubMed Close
,
Ahouefa Kowo-Bille Endocrine Oncology Department, Saint-Louis Hospital (AP-HP), Université Paris Cité, Paris, France

Search for other papers by Ahouefa Kowo-Bille in
Google Scholar
PubMed Close
,
Clement Dumont Medical Oncology Department, Saint-Louis Hospital (AP-HP), Université Paris Cité, Paris, France

Search for other papers by Clement Dumont in
Google Scholar
PubMed Close
, and
Cécile N Chougnet Endocrine Oncology Department, Saint-Louis Hospital (AP-HP), Université Paris Cité, Paris, France

Search for other papers by Cécile N Chougnet in
Google Scholar
PubMed Close

patients with familial MTC have a RET germline mutation ( 2 ). The gold-standard systemic treatment for metastatic MTC is vandetanib. Numerous intratumoral RET mutations exist, leading to heterogeneous phenotypes in terms of aggressiveness ( 3 ). The

Article Type:
Case Report
Collections:
Thyroid cancer - clinical
DOI:
https://doi.org/10.1530/ETJ-22-0032
Volume/Issue:
Volume 11: Issue 6
Open access
Stéphane Bardet Department of Nuclear Medicine and Thyroid Unit, Centre François Baclesse, Caen, France

Search for other papers by Stéphane Bardet in
Google Scholar
PubMed Close
,
Renaud Ciappuccini Department of Nuclear Medicine and Thyroid Unit, Centre François Baclesse, Caen, France

Search for other papers by Renaud Ciappuccini in
Google Scholar
PubMed Close
,
Livia Lamartina Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy, Villejuif, France

Search for other papers by Livia Lamartina in
Google Scholar
PubMed Close
, and
Sophie Leboulleux Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy, Villejuif, France

Search for other papers by Sophie Leboulleux in
Google Scholar
PubMed Close

which recently proved as highly efficient and well-tolerated in phase 1–2 trial including RET -mutant MTC patients. The tumour response rate according to RECIST 1.1 was 69% in the 55 patients who had previously received vandetanib, cabozantinib, or both

Article Type:
Case Report
Collections:
Thyroid cancer - clinical
DOI:
https://doi.org/10.1530/ETJ-21-0104
Volume/Issue:
Volume 11: Issue 2
Open access
Carla Gambale Department of Clinical and Experimental Medicine, Unit of Endocrinology, Pisa University Hospital, Pisa, Italy

Search for other papers by Carla Gambale in
Google Scholar
PubMed Close
,
Alessandro Prete Department of Clinical and Experimental Medicine, Unit of Endocrinology, Pisa University Hospital, Pisa, Italy

Search for other papers by Alessandro Prete in
Google Scholar
PubMed Close
,
Chiara Romei Department of Diagnostic Imaging, Unit of Radiology, Pisa University Hospital, Pisa, Italy

Search for other papers by Chiara Romei in
Google Scholar
PubMed Close
,
Alessandro Celi Department of Surgery, Medicine, Molecular Biology and Critical Care, Respiratory Pathophysiology Unit, Pisa University Hospital, Pisa, Italy

Search for other papers by Alessandro Celi in
Google Scholar
PubMed Close
,
Rossella Elisei Department of Clinical and Experimental Medicine, Unit of Endocrinology, Pisa University Hospital, Pisa, Italy

Search for other papers by Rossella Elisei in
Google Scholar
PubMed Close
, and
Antonio Matrone Department of Clinical and Experimental Medicine, Unit of Endocrinology, Pisa University Hospital, Pisa, Italy

Search for other papers by Antonio Matrone in
Google Scholar
PubMed Close

advanced/metastatic ( 1 ). According to European Medicines Agency (EMA) indications, two multikinase inhibitors (MKIs) (i.e. vandetanib and cabozantinib) and one highly selective RET inhibitor (i.e. selpercatinib) have been approved for the treatment of

Article Type:
Case Report
Collections:
Thyroid cancer - clinical
DOI:
https://doi.org/10.1530/ETJ-24-0189
Volume/Issue:
Volume 13: Issue 5
Open access
M. Schlumberger Department of Nuclear Medicine and Endocrine Oncology, Institute Gustave-Roussy and University Paris Sud, Villejuif, France

Search for other papers by M. Schlumberger in
Google Scholar
PubMed Close
,
L. Bastholt Department of Oncology, Odense University Hospital, Odense, Denmark

Search for other papers by L. Bastholt in
Google Scholar
PubMed Close
,
H. Dralle Department of Surgery, Martin Luther University, Halle-Wittenberg Medical Faculty, Halle/Saale, Germany

Search for other papers by H. Dralle in
Google Scholar
PubMed Close
,
B. Jarzab MSC Memorial Cancer Center and Institute of Oncology, Gliwice, Poland

Search for other papers by B. Jarzab in
Google Scholar
PubMed Close
,
F. Pacini Department of Endocrinologia, University of Siena, Siena, Italy

Search for other papers by F. Pacini in
Google Scholar
PubMed Close
, and
J.W.A. Smit Department of Endocrinology, Leiden University Medical Centre, Leiden, The Netherlands

Search for other papers by J.W.A. Smit in
Google Scholar
PubMed Close

clinical trials, including axitinib, cabozantinib (XL-184), lenvatinib (E7080), motesanib, pazopanib, sorafenib, sunitinib and vandetanib [ 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 ]. In phase II trials, several of these agents have demonstrated

Article Type:
Guideline
DOI:
https://doi.org/10.1159/000336977
Volume/Issue:
Volume 1: Issue 1
Free access
Francesca Carlomagno Dipartimento di Biologia e Patologia Cellulare e Molecolare L. Califano, Università degli Studi di Napoli Federico II, Napoli, Italia

Search for other papers by Francesca Carlomagno in
Google Scholar
PubMed Close

to their toxicity or limited bioavailability. Another group of anti-RET compounds that had been tested in phase I clinical trials has been described. Such molecules comprise vandetanib, sorafenib, sunitinib, cabozantinib and lenvatinib [ 40 , 41

Article Type:
Review Article
DOI:
https://doi.org/10.1159/000336975
Volume/Issue:
Volume 1: Issue 1
Free access